

Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: [JNJ US EQUITY](#)

Johnson & Johnson (New York: JNJ, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos


Website	www.jnj.com
Number of Employees	134,500
Ticker:	JNJ US

1 Johnson & Johnson Plaza New Brunswick, NJ 08933 United States
Phone : 1-732-524-0400
Fax : --

↓ **171.63** -1.13 (-0.65%)

FECHA: 30/06/2021

Stock Quote & Chart (Currency: USD)			
Last (delayed quote)	171.63	Market Cap (MM)	451,832.6
Open	171.00	Shares Out. (MM)	2,632.6
Previous Close	172.76	Float %	99.9%
Change	-0.01	Shares sold short (MM)	14,406,499.0
Change %	-0.01	Dividend Yield %	2.4
Day High/Day Low	173.0 / 170.1	Diluted EPS Excl. XO	8.3
52 Wk High/52 Wk low	179.9 / 151.5	P / Diluted EPS Before XO	22.0
Volume (MM)	6.22	Beta	0.71
Avg. Vol - 3 mo (MM)	7.90		



Financial Information (Currency: USD, in mm)			
Revenue - LTM	93,775.0	Cash & ST Invest.	25,185
EBIT - LTM	23,647.0	Total Assets	174,894.0
EBITDA - LTM	30,294.0	Total Debt	35,266.0
Net Income - LTM	20,878.0	Total Liabilities	111,616.0
Total Enterprise Value	454,760	Total Equity	63,278.0
TEV/ Total Revenue	4.7 x	Cash from Operations - LTM	26,021.0
TEV/ EBITDA	14.0 x	Cash From Investing - LTM	-11,226.0
		Cash from Financing -LTM	-16,156.0


Company Notes	
2016 Q1 GAAP Net Income Includes: (in millions, pre-tax) A gain of \$402.000 from Litigation / Settlement A loss of \$137 from Restructuring A loss of \$66 from Litigation	GAAP Net Income Includes: (in millions, pre-tax) A gain of \$402.000 from Litigation / Settlement A loss of \$139.000 from Other One-Time Charges A loss of \$32.000 from Merger expense A gain of \$76.000 from Sale of Business
2015 A1 GAAP Net Income includes: (in millions, pre-tax): a total loss of \$1,237.000	2014 A1 GAAP Net Income Includes: (in millions, pre-tax) A gain of \$1,899.00 from sale of business A loss of \$1,253.000 from Legal Expense
2015 Q4 GAAP Net Income includes: (in millions, pre-tax): a loss of \$214.000 from Acquired In-Process R&D Expense a gain of \$33.000 from Sale of Business a loss of \$590.000 from Restructuring Charges a loss of \$83.000 from Other One-Time Charges	2014 Q4 GAAP Net Income Includes: (in millions, pre-tax) A loss of \$692.000 from Legal/Litigation A loss of \$325.000 from Merger/Acquisition Expense A loss of \$156.000 from Acquired In-Process RD A loss of \$49.000 from Sale of Business
2015 Q3 GAAP Net Income Includes: (in millions, pre-tax) A loss of \$409.000 from Legal Expense A loss of \$32.000 from Merger/Acquisition Expense A loss of \$10.000 from Acquired In-Process RD	2014 Q3 GAAP Net Income Includes: (in millions, pre-tax) A gain of \$1948.000 from Sale of Business A loss of \$346.000 from Other One Time Items A loss of \$285.000 from Legal Expense A loss of \$167.000 from Merger/Acquisition Expense
2015 Q2 GAAP Net Income Includes: (in millions, pre-tax) A loss of \$134.000 from Legal Expense A loss of \$49.000 from Merger/Acquisition Expense A loss of \$9.000 from Other One Time Items A gain of \$3.000 from Sale of Business	2014 Q2
2015 Q1	2014 Q1

Key Board Members		
Name	Title	Organization
Charles Prince	Chairman	Scnset Group
Anne M Mulcahy	Board Member	Johnson & Johnson
	Partner	Lead Edge Capital
Mark A Weinberger	Board Member	Williams-Sonoma Inc
	Board Member	Graham Holdings Co
	Board Member	Lpl Financial Holdings Inc
	Lead Director	Johnson & Johnson
	Co-Founder	Washington Counsel Pc
	Senior Advisor	Stone Canyon Industries Holdin
Hubert Joly	Board Member	Saudi Arabian Oil Co
	Board Member	Johnson & Johnson
	Board Member	MetLife Inc
	Board Member	Concord Coalition
	Board Member	National Bureau Of Economic Re
Mark B Mccllellan	Trustee	United States Council For Inte
	Board Member	Bullis School
	Trustee	Case Western Reserve Universit
	Lead Director	Ralph Lauren Corp
Ian E L Davis	Board Member	Johnson & Johnson
	Board Member	Minnesota Business Partnership
	Founding Dir:Margolis Center For	Duke University
	Senior Advisor	Blackstone Group Inc
	Board Member	Cigna Corp
Ian E L Davis	Board Member	Gary & Mary West Wireless Heal
	Board Member	Alignment Healthcare Inc
	Board Member	Johnson & Johnson
	Board Member	Arbormetrix Inc
	Senior Advisor	Apax Partners Llp
Chairman		Vickers Pension Trustees Ltd

Ticker:	jnj US EQUITY										
Period Type:	Annuals										
Annuals	Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos										
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY


Key Financials	Actuals											LTM		Estimates	
	For the Fiscal Period Ending	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	03/10/2021	02/01/2022	31/12/2022	31/12/2023	31/12/2024			
Currency	USD											USD	USD	USD	USD
Total Revenue	70,074.0	71,890.0	76,450.0	81,581.0	82,059.0	82,584.0	93,775.0	93,775.0	23,786.8	23,786.8	23,786.8	23,786.8			
<i>Growth Over Prior Year</i>	(5.7%)	2.6%	6.3%	6.7%	0.6%	0.6%	13.6%	13.6%	6.6%	6.6%	6.6%	6.6%			30/06/2021
Gross Profit	48,538.0	50,205.0	51,011.0	54,490.0	54,503.0	54,157.0	63,920.0	63,920.0	--	--	--	--			--
<i>Margin %</i>	69.3%	69.8%	66.7%	66.8%	66.4%	65.6%	68.2%	68.2%	--	--	--	--			--
EBITDA	21,811.0	24,890.0	24,131.0	26,978.0	27,389.0	26,964.0	26,964.0	--	9,042.8	9,042.8	9,042.8	9,042.8			
<i>Margin %</i>	31.1%	34.6%	31.6%	33.1%	33.4%	32.7%	28.8%	--	38.0%	38.0%	38.0%	38.0%			
EBIT	18,065.0	21,136.0	18,489.0	20,049.0	20,080.0	19,733.0	23,647.0	23,647.0	7,831.1	7,831.1	7,831.1	7,831.1			
<i>Margin %</i>	25.8%	29.4%	24.2%	24.6%	24.5%	23.9%	25.2%	25.2%	32.9%	32.9%	32.9%	32.9%			
Earnings from Cont. Ops.	15,409.0	16,540.0	1,300.0	15,297.0	15,119.0	14,714.0	20,878.0	20,878.0	--	--	--	--			
<i>Margin %</i>	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	22.3%	22.3%	--	--	--	--			
Net Income	15,409.0	16,540.0	1,300.0	15,297.0	15,119.0	14,714.0	20,878.0	20,878.0	6,951.8	6,951.8	6,951.8	6,951.8			
<i>Margin %</i>	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	22.3%	22.3%	29.2%	29.2%	29.2%	29.2%			
Diluted EPS Excl. Extra Items	5.5	5.9	0.5	5.6	5.6	5.5	7.8	7.8	2.6	2.6	2.6	2.6			
<i>Growth Over Prior Year</i>	(3.9%)	8.2%	(92.1%)	1,093.6%	0.4%	(2.1%)	41.7%	41.7%	0.2%	0.2%	0.2%	0.2%			

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	171.63
Shares Out.	2,632.60
Market Capitalization (USD)	451,832.62
- Cash & Short Term Investments	0.00
+ Total Debt	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	454,759.62
Book Value of Common Equity	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	0.00
= Total Capital	0.00



Valuation Multiples based on Current Capitalization				
For the Fiscal Period Ending	Actual	LTM	Estimates	
	03/10/2021	02/01/2022	03/10/2021	03/10/2021
TEV/Total Revenue	5.1x	--	19.1x	19.1x
TEV/EBITDA	15.7x	--	12.5x	12.5x
TEV/EBIT	21.5x	--	14.3x	14.3x
P/Diluted EPS Before Extra	21.9x	21.9x		
P/BV	6.5x	--	6.1x	6.1x
Price/Tang BV	--	--		

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	20.6x	16.4x	16.4x	16.4x
TEV / EBITDA	14.0x	12.5x	12.5x	12.5x
Price / CF	17.4x	14.7x	14.7x	14.7x
Price / Book	6.4x	6.1x	6.1x	6.1x
Dividend Yield	2.4x	2.5x	2.5x	2.5x



Ticker:	jnj US EQUITY
Period Type	Annuals

jnj US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Income Statement											
Income Sheet as of:	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	-
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Cost Of Goods Sold	20,360.00	21,658.00	22,342.00	22,746.00	21,536.00	21,685.00	25,439.00	27,091.00	27,556.00	28,427.00	29,855.00
Gross Profit	44,670.00	45,566.00	48,970.00	51,585.00	48,538.00	50,205.00	51,011.00	54,490.00	54,503.00	54,157.00	63,920.00
Selling General & Admin Exp.	21,538.00	22,032.00	22,410.00	22,132.00	21,427.00	19,974.00	21,928.00	23,666.00	23,068.00	22,265.00	25,559.00
R & D Exp.	7,548.00	7,665.00	8,183.00	8,494.00	9,046.00	9,095.00	10,594.00	10,775.00	11,355.00	12,159.00	14,714.00
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	29,086.00	29,697.00	30,593.00	30,626.00	30,473.00	29,069.00	32,522.00	34,441.00	34,423.00	34,424.00	40,273.00
Operating Income	15,584.00	15,869.00	18,377.00	20,959.00	18,065.00	21,136.00	18,489.00	20,049.00	20,080.00	19,733.00	23,647.00
Interest Expense	571.00	532.00	482.00	533.00	552.00	726.00	934.00	1,005.00	318.00	201.00	-
Interest Income	91.00	64.00	74.00	67.00	128.00	368.00	385.00	611.00	357.00	111.00	-
Net Interest Exp.	480.00	468.00	408.00	466.00	424.00	358.00	549.00	394.00	(39.00)	90.00	-
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	1,277.00	574.00	852.00	1,088.00	910.00	863.00	619.00	1,151.00	930.00	3,257.00	871.00
EBT Excl. Unusual Items	13,827.00	14,827.00	17,117.00	19,405.00	16,731.00	19,915.00	17,321.00	18,504.00	19,189.00	16,386.00	22,776.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	(2,383.00)	(2,583.00)	(563.00)	(1,307.00)	(1,217.00)	(2,154.00)	(111.00)	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	1,466.00	1,052.00	1,646.00	1,225.00	118.00	675.00	955.00	1,722.00	4,015.00	-	-
Other Unusual Items	(2,932.00)	(2,104.00)	(3,292.00)	2,316.00	4,930.00	(224.00)	704.00	(1,010.00)	(3,722.00)	222.00	-
EBT Incl. Unusual Items	12,361.00	13,775.00	15,471.00	20,563.00	19,196.00	19,803.00	17,673.00	17,999.00	17,328.00	16,497.00	22,776.00
Income Tax Expense	2,689.00	3,261.00	1,640.00	4,240.00	3,787.00	3,263.00	16,373.00	2,702.00	2,209.00	1,783.00	1,898.00
Earnings from Cont. Ops.	9,672.00	10,514.00	13,831.00	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	-	(339.00)	-	-	-	-	-	-	-	-	-
Net Income	9,672.00	10,853.00	13,831.00	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	9,672.00	10,853.00	13,831.00	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00
Abnormal Losses (Gains)	4,992.00	4,439.00	3,643.00	(1,751.00)	(671.00)	1,685.00	3,752.00	4,270.00	6,413.00	4,713.00	3,464.00
Tax Effect on Abnormal Items	(797.00)	(947.00)	(1,633.75)	984.05	241.85	(342.90)	12,507.00	(1,286.70)	(1,885.07)	(1,371.90)	(1,588.37)
NI to Common Excl. Extra Items	13,867.00	14,345.00	15,840.25	15,556.05	14,979.85	17,882.10	17,559.00	18,280.30	19,646.93	18,055.10	22,753.63
Per Share Items											
Basic EPS	3.54	3.94	4.92	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.81
Basic EPS Excl. Extra Items	3.54	3.94	4.92	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.81
Weighted Avg. Basic Shares Out.	2,736.00	2,753.30	2,809.20	2,815.20	2,771.80	2,737.30	2,692.00	2,681.50	2,645.10	2,632.80	2,674.00
Diluted EPS	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81
Diluted EPS Excl. Extra Items	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81
Weighted Avg. Diluted Shares Out.	2,775.30	2,812.60	2,877.00	2,863.90	2,812.90	2,788.90	2,745.30	2,728.70	2,684.30	2,670.70	2,674.00
Normalized Basic EPS	5.00	5.10	5.52	5.97	6.20	6.73	7.30	8.18	8.68	8.03	9.80
Normalized Diluted EPS	5.00	5.10	5.51	5.43	5.33	6.41	6.39	6.70	7.32	6.76	8.51
Dividends per Share	2.25	2.40	2.59	2.76	2.95	3.15	3.32	3.54	3.75	3.98	4.19
Payout Ratio %	63.65	60.89	52.61	47.60	53.07	52.13	687.50	62.05	65.61	71.21	53.66
Supplemental Items											
EBITA	16,442.00	17,035.00	19,781.00	22,354.00	19,311.00	22,390.00	21,531.00	24,378.00	24,889.00	24,364.00	28,344.00
EBIT	15,584.00	15,869.00	18,377.00	20,959.00	18,065.00	21,136.00	18,489.00	20,049.00	20,080.00	19,733.00	23,647.00
As Reported Total Revenue*	65,030.00	-	-	-	-	-	-	81,581.00	82,059.00	82,584.00	93,775.00
Effective Tax Rate %	21.75	23.67	10.60	20.62	19.73	16.48	92.64	15.01	12.75	10.81	8.33
Normalized Net Income	13,867.00	14,345.00	15,840.25	15,556.05	14,979.85	17,882.10	17,559.00	18,280.30	19,646.93	18,055.10	22,753.63
Interest Capitalized	84.00	115.00	105.00	115.00	102.00	102.00	94.00	86.00	70.00	63.00	-
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	621.00	662.00	728.00	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	-
Stock-Based Comp., Total	621.00	662.00	728.00	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	-

Ticker:	jnj US EQUITY
Period Type	Annuals

jnj US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Balance Sheet	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	--
Balance Sheet as of:	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	24,542.00	14,911.00	20,927.00	14,523.00	13,732.00	18,972.00	17,824.00	18,107.00	17,305.00	13,985.00	-
Short Term Investments	7,719.00	6,178.00	8,279.00	18,566.00	24,644.00	22,935.00	472.00	1,580.00	1,982.00	11,200.00	-
Total Cash & ST Investments	32,261.00	21,089.00	29,206.00	33,089.00	38,376.00	41,907.00	18,296.00	19,687.00	19,287.00	25,185.00	-
Accounts & Notes Receivable	10,581.00	11,309.00	11,713.00	10,985.00	10,734.00	11,699.00	13,490.00	14,098.00	14,481.00	13,576.00	-
Total Receivables	10,581.00	11,309.00	11,713.00	10,985.00	10,734.00	11,699.00	13,490.00	14,098.00	14,481.00	13,576.00	-
Inventories	6,285.00	7,495.00	7,878.00	8,184.00	8,053.00	8,144.00	8,765.00	8,599.00	9,020.00	9,344.00	-
Prepaid Exp.	2,633.00	3,084.00	4,003.00	3,486.00	3,047.00	3,282.00	2,537.00	2,699.00	2,392.00	3,132.00	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2,556.00	3,139.00	3,607.00	-	-	-	-	950.00	94.00	-	-
Total Current Assets	54,316.00	46,116.00	56,407.00	55,744.00	60,210.00	65,032.00	43,088.00	46,033.00	45,274.00	51,237.00	-
Net Property, Plant & Equipment	14,739.00	16,097.00	16,710.00	16,126.00	15,905.00	15,912.00	17,005.00	17,035.00	18,615.00	18,766.00	-
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	6,540.00	4,541.00	3,872.00	6,202.00	5,490.00	6,148.00	7,105.00	7,640.00	7,819.00	8,534.00	-
Other Long-Term Assets	38,049.00	54,593.00	55,694.00	52,286.00	51,806.00	54,116.00	90,105.00	82,246.00	86,020.00	96,357.00	-
Total Assets	113,644.00	121,347.00	132,683.00	130,358.00	133,411.00	141,208.00	157,303.00	152,954.00	157,728.00	174,894.00	-
LIABILITIES											
Accrued Exp.	9,574.00	12,691.00	13,787.00	13,314.00	13,325.00	13,714.00	17,467.00	20,079.00	23,952.00	28,965.00	-
Short-term Borrowings	6,658.00	4,676.00	4,852.00	3,638.00	7,004.00	4,684.00	3,906.00	2,796.00	1,471.00	2,631.00	-
Accounts Payable	5,725.00	5,831.00	6,266.00	7,633.00	6,668.00	6,918.00	7,310.00	7,537.00	8,544.00	9,505.00	-
Curr. Income Taxes Payable	854.00	1,064.00	770.00	446.00	750.00	971.00	1,854.00	818.00	2,266.00	1,392.00	-
Other Current Liabilities	-	-	-	-	-	-	-	-	(269.00)	-	-
Total Current Liabilities	22,811.00	24,262.00	25,675.00	25,031.00	27,747.00	26,287.00	30,537.00	31,230.00	35,964.00	42,493.00	-
Long-Term Debt	12,969.00	11,489.00	13,328.00	15,122.00	12,857.00	22,442.00	30,675.00	27,684.00	27,210.00	32,635.00	-
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	20,784.00	20,770.00	19,627.00	20,453.00	21,657.00	22,061.00	35,931.00	34,288.00	35,083.00	36,488.00	-
Total Liabilities	56,564.00	56,521.00	58,630.00	60,606.00	62,261.00	70,790.00	97,143.00	93,202.00	98,257.00	111,616.00	-
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
Total Pref. Equity	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Additional Paid In Capital	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	-
Retained Earnings	81,251.00	85,992.00	89,493.00	97,245.00	103,879.00	110,551.00	101,793.00	106,216.00	110,659.00	113,890.00	-
Treasury Stock	(21,659.00)	(18,476.00)	(15,700.00)	(19,891.00)	(22,684.00)	(28,352.00)	(31,554.00)	(34,362.00)	(38,417.00)	(38,490.00)	-
Comprehensive Inc. and Other	(5,632.00)	(5,810.00)	(2,860.00)	(10,722.00)	(13,165.00)	(14,901.00)	(13,199.00)	(15,222.00)	(15,891.00)	(15,242.00)	-
Total Common Equity	57,080.00	64,826.00	74,053.00	69,752.00	71,150.00	70,418.00	60,160.00	59,752.00	59,471.00	63,278.00	-
Total Equity	57,080.00	64,826.00	74,053.00	69,752.00	71,150.00	70,418.00	60,160.00	59,752.00	59,471.00	63,278.00	-
Total Liabilities And Equity	113,644.00	121,347.00	132,683.00	130,358.00	133,411.00	141,208.00	157,303.00	152,954.00	157,728.00	174,894.00	-
Supplemental Items											
Total Shares Out. on Filing Date	2,724.36	2,778.49	2,820.63	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	-
Total Shares Out. on Balance Sheet Date	2,724.36	2,778.49	2,820.63	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	-
Book Value/Share	20.95	23.33	26.25	25.06	25.82	26.02	22.43	22.44	22.59	24.04	-
Tangible Book Value	22,804.00	13,650.00	23,308.00	20,698.00	23,757.00	20,737.00	(24,974.00)	(18,312.00)	(21,811.00)	(26,517.00)	-
Tangible Book Value/Share	8.37	4.91	8.26	7.44	8.62	7.66	(9.31)	(6.88)	(8.29)	(10.07)	-
Total Debt	19,627.00	16,165.00	18,180.00	18,760.00	19,861.00	27,126.00	34,581.00	30,480.00	28,681.00	35,266.00	-
Net Debt	(12,634.00)	(4,924.00)	(11,026.00)	(14,329.00)	(18,515.00)	(14,781.00)	16,285.00	10,793.00	9,394.00	10,081.00	-
Total Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	1,206.00	1,416.00	1,224.00	1,214.00	936.00	952.00	1,140.00	1,114.00	1,117.00	1,410.00	-
Work in Progress Inventory	1,637.00	2,262.00	2,612.00	2,461.00	2,241.00	2,185.00	2,317.00	2,109.00	1,832.00	2,040.00	-
Finished Goods Inventory	3,442.00	3,817.00	4,042.00	4,509.00	4,876.00	5,007.00	5,308.00	5,376.00	6,071.00	5,894.00	-
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	361.00	466.00	333.00	275.00	268.00	252.00	291.00	248.00	226.00	293.00	-
Full Time Employees	117,900.00	127,600.00	128,100.00	126,500.00	127,100.00	126,400.00	134,000.00	135,100.00	132,200.00	134,500.00	-

Ticker: **jnj US EQUITY**
 Period Type: **Annuals**

Sort: **Ascend**
 Consolidated: **Yes**

Accounting: **Mixed**

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Multiples		01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	--
TEV / LTM Total Revenue	Close	2.6x	2.8x	3.5x	3.7x	3.8x	4.1x	5.1x	4.3x	4.8x	5.1x	--
	Average	2.6x	2.6x	3.5x	3.8x	3.5x	4.2x	4.7x	4.9x	4.5x	4.8x	5.4x
	High	2.8x	2.9x	3.9x	4.1x	3.8x	4.7x	5.2x	5.4x	4.9x	5.1x	5.8x
	Low	2.4x	2.4x	2.8x	3.3x	3.2x	3.5x	4.0x	4.3x	4.2x	3.7x	5.0x
TEV / LTM EBITDA	Close	8.9x	9.6x	11.1x	11.2x	12.1x	11.9x	16.2x	13.0x	14.4x	15.7x	--
	Average	8.4x	9.2x	12.0x	12.1x	10.6x	13.4x	13.5x	15.5x	13.7x	14.4x	16.5x
	High	9.0x	10.0x	13.6x	13.1x	12.2x	15.0x	16.2x	17.2x	14.7x	15.7x	17.9x
	Low	7.5x	8.4x	9.7x	10.4x	9.5x	11.3x	11.6x	13.1x	12.8x	11.0x	15.3x
TEV / LTM EBIT	Close	10.7x	11.9x	13.6x	13.3x	14.6x	14.1x	21.2x	17.4x	19.5x	21.5x	--
	Average	9.9x	11.0x	14.8x	14.8x	12.5x	16.2x	15.9x	20.2x	18.4x	19.6x	22.6x
	High	10.7x	12.0x	16.7x	16.1x	14.7x	18.1x	21.2x	22.4x	19.8x	21.5x	24.5x
	Low	8.9x	10.1x	11.9x	12.7x	11.3x	13.6x	13.7x	17.6x	17.2x	15.0x	20.9x
Price / LTM EPS	Close	13.1x	13.6x	16.8x	19.3x	19.3x	18.0x	21.9x	19.0x	19.9x	23.3x	20.1x
	Average	13.3x	13.4x	16.8x	18.3x	18.4x	21.3x	20.2x	20.8x	20.1x	19.9x	24.5x
	High	14.3x	14.5x	18.7x	19.8x	19.6x	23.5x	22.4x	23.2x	21.8x	23.3x	26.5x
	Low	12.1x	12.4x	13.7x	15.7x	16.7x	18.0x	17.4x	18.7x	18.8x	15.2x	20.1x
Price / Book Value	Close	3.1x	3.0x	3.5x	4.2x	4.0x	4.4x	6.2x	5.7x	6.5x	6.5x	--
	Average	3.1x	3.2x	3.7x	3.8x	4.0x	4.4x	5.0x	5.9x	6.0x	6.5x	6.9x
	High	3.3x	3.5x	4.1x	4.2x	4.2x	4.9x	6.2x	6.6x	6.5x	6.9x	7.5x
	Low	2.8x	2.9x	3.0x	3.3x	3.6x	3.7x	4.3x	5.3x	5.6x	4.9x	6.4x
Price / Tangible Book Value	Close	7.8x	14.1x	11.2x	14.1x	11.9x	15.0x	--	--	--	--	--
	Average	7.1x	8.0x	17.4x	12.2x	13.4x	13.2x	16.9x	--	--	--	--
	High	7.8x	14.1x	19.5x	14.1x	14.3x	15.0x	18.7x	--	--	--	--
	Low	6.4x	7.4x	11.2x	10.5x	11.9x	11.1x	14.6x	--	--	--	--
Price / Cash Flow	Close	12.5x	12.4x	14.9x	15.8x	14.5x	16.8x	17.9x	15.4x	16.5x	17.6x	--
	Average	10.7x	12.8x	15.3x	16.2x	15.0x	16.1x	18.9x	17.0x	16.3x	16.5x	18.5x
	High	12.5x	13.9x	17.1x	17.6x	16.0x	17.8x	20.9x	18.9x	17.7x	17.6x	20.1x
	Low	9.7x	11.8x	12.5x	14.0x	13.7x	13.6x	16.3x	15.3x	15.2x	12.6x	17.1x
TEV / LTM FCF	Close	15.7x	15.4x	18.8x	19.7x	17.7x	20.3x	21.2x	18.4x	19.4x	20.5x	--
	Average	12.5x	16.1x	18.9x	20.5x	18.7x	19.6x	22.8x	20.1x	19.5x	19.4x	21.6x
	High	15.7x	17.4x	21.1x	22.2x	20.0x	21.6x	25.3x	22.4x	21.2x	20.7x	23.4x
	Low	11.3x	14.8x	15.5x	17.6x	17.0x	16.5x	19.7x	18.1x	18.2x	14.8x	20.0x
Dividend Yield	Close	3.4	3.5	2.8	2.6	2.9	2.7	2.4	2.8	2.6	2.5	2.4
	Average	3.3	3.4	2.8	2.6	2.8	2.6	2.4	2.5	2.6	2.6	2.4
	High	3.7	3.6	3.4	3.0	3.0	3.1	2.8	2.8	2.8	3.4	2.6
	Low	3.1	3.1	2.5	2.4	2.6	2.4	2.2	2.2	2.4	2.4	2.2

Ticker:	jnj US EQUITY
Period Type	Quarters

jnj US EQUITY	Ascend
Consolidated	Yes

Accounting	Mixed
------------	-------

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Ratios	30/06/2019	29/09/2019	29/12/2019	29/03/2020	28/06/2020	27/09/2020	03/01/2021	04/04/2021	04/07/2021	03/10/2021	--
Profitability											
Return on Assets	10.5%	9.1%	9.7%	11.3%	9.7%	10.4%	8.8%	9.2%	10.6%	10.2%	--
Return on Capital	18.2%	15.8%	17.3%	19.5%	16.7%	18.0%	16.0%	16.3%	18.3%	17.5%	--
Return on Equity	26.4%	23.0%	25.4%	28.6%	24.5%	27.7%	24.0%	23.8%	26.8%	26.5%	--
Margin Analysis											
Gross Margin	66.2%	66.9%	65.6%	65.9%	64.1%	66.9%	65.2%	68.4%	67.5%	68.9%	67.9%
SG&A Margin	27.0%	25.9%	29.1%	25.1%	27.2%	25.7%	28.7%	24.3%	26.0%	25.7%	28.8%
EBITDA Margin	31.6%	33.2%	33.4%	34.7%	34.7%	33.5%	32.7%	33.1%	33.9%	33.1%	--
EBIT Margin	22.9%	24.4%	24.5%	26.0%	25.0%	24.7%	23.9%	24.4%	25.5%	24.9%	25.2%
Earnings from Cont. Ops Margin	26.3%	28.4%	20.9%	28.3%	22.1%	27.0%	18.4%	29.8%	26.8%	24.7%	20.1%
Net Income Margin	27.3%	8.5%	19.3%	28.0%	19.8%	16.9%	7.7%	27.8%	26.9%	15.7%	19.1%
Normalized Net Income Margin	29.0%	23.0%	20.4%	26.3%	19.3%	24.6%	17.8%	26.4%	24.0%	25.6%	19.5%
Free Cash Flow Margin	24.9%	32.7%	24.8%	13.2%	15.2%	36.3%	31.2%	15.2%	19.3%	32.3%	--
Asset Turnover											
Total Asset Turnover	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	--
Fixed Asset Turnover	4.7x	4.7x	4.6x	4.7x	4.5x	4.5x	4.4x	4.7x	4.9x	5.0x	--
Accounts Receivable Turnover	5.7x	5.7x	5.7x	5.7x	5.5x	5.5x	5.9x	5.6x	6.0x	6.2x	--
Inventory Turnover	3.0x	3.1x	3.1x	3.1x	3.0x	3.0x	3.1x	3.0x	3.0x	3.0x	--
Short Term Liquidity											
Current Ratio	1.3x	1.3x	1.3x	1.3x	1.2x	1.5x	1.2x	1.3x	1.4x	1.3x	--
Quick Ratio	1.0x	0.9x	0.9x	1.0x	0.9x	1.2x	0.9x	1.0x	1.0x	1.0x	--
Cash from Ops. To Curr Liab	0.5x	0.5x	0.5x	0.5x	0.5x	0.8x	0.6x	0.6x	0.7x	0.7x	--
Ave. Davs Sales Out.	64.4x	64.3x	63.4x	63.8x	66.2x	66.1x	63.0x	65.7x	61.4x	59.8x	--
Ave. Davs Inventory Out.	121.4x	118.6x	116.4x	116.7x	123.0x	123.1x	119.8x	122.8x	123.0x	124.8x	--
Ave. Davs Pivable Out.	88.7x	94.6x	104.6x	93.9x	89.5x	93.9x	116.5x	100.0x	95.3x	97.3x	--
Ave. Cash Conversion Cvcle	97.0x	88.3x	75.1x	86.6x	99.7x	95.4x	66.4x	88.4x	89.1x	87.3x	--
Long Term Solvency											
Total Debt/Equity	50.1%	51.9%	48.2%	45.0%	48.3%	58.6%	55.7%	51.1%	48.1%	48.3%	--
Total Debt/Capital	33.4%	34.2%	32.5%	31.0%	32.6%	36.9%	35.8%	33.8%	32.5%	32.6%	--
LT Debt/Equity	46.8%	47.5%	45.8%	41.4%	39.8%	50.7%	51.6%	46.0%	43.6%	42.9%	--
LT Debt/Capital	31.2%	31.3%	30.9%	28.6%	26.8%	32.0%	33.1%	30.4%	29.4%	28.9%	--
Total Liabilities/Total Assets	40.6%	40.0%	39.5%	38.7%	37.0%	39.5%	39.5%	38.1%	38.6%	35.9%	--
EBIT / Interest Exp.	65.18x	122.69x	51.08x	233.84x	90.02x	129.57x	47.53x	105.52x	156.45x	288.30x	--
EBITDA / Interest Exp.	86.33x	160.81x	73.39x	303.72x	142.76x	156.18x	69.83x	135.59x	219.78x	344.30x	--
(EBITDA-CAPEX) / Interest Exp.	76.24x	145.29x	58.56x	278.72x	128.04x	139.43x	54.62x	124.84x	199.45x	306.95x	--
Total Debt/EBITDA	1.18x	1.11x	1.05x	0.96x	1.09x	1.39x	1.31x	1.20x	1.11x	1.12x	--
Net Debt/FRITDA	0.59x	0.45x	0.34x	0.33x	0.40x	0.76x	0.37x	0.37x	0.37x	0.10x	--
Altman Z Score	6.64	6.28	6.46	6.45	6.4	5.86	5.96	6.25	6.38	6.02	--
Growth Over Prior Year											
Total Revenue	(1.3%)	1.9%	1.7%	3.3%	(10.8%)	1.7%	8.3%	7.9%	27.1%	10.7%	10.4%
Gross Profit	(2.0%)	0.7%	1.3%	1.7%	(13.7%)	1.8%	7.7%	12.0%	33.8%	14.0%	14.9%
EBITDA	(1.0%)	22.3%	4.8%	21.0%	(10.3%)	(11.0%)	(2.6%)	12.5%	36.8%	0.2%	--
EBITA	(1.2%)	24.0%	3.6%	25.0%	(37.9%)	(11.3%)	(2.1%)	12.9%	54.5%	(0.1%)	13.5%
EBIT	(2.0%)	28.5%	2.9%	31.7%	(25.1%)	(3.2%)	(4.8%)	13.7%	54.5%	1.1%	20.3%
Earnings from Cont. Ops.	41.8%	(55.4%)	31.8%	54.6%	(35.3%)	102.7%	(56.7%)	6.9%	73.1%	3.2%	172.5%
Net Income	41.8%	(55.4%)	31.8%	54.6%	(35.3%)	102.7%	(56.7%)	6.9%	73.1%	3.1%	172.5%
Normalized Net Income	25.7%	3.3%	(4.3%)	13.0%	(40.8%)	8.6%	(5.2%)	8.2%	58.0%	15.2%	20.7%
Diluted EPS before Extra	43.4%	(54.2%)	33.9%	56.1%	(34.6%)	101.5%	(56.7%)	6.9%	72.8%	3.0%	172.3%
Accounts Receivable	3.8%	5.4%	2.7%	5.4%	(0.1%)	(1.5%)	(6.2%)	0.4%	1.5%	2.3%	--
Inventory	5.1%	5.7%	4.9%	(2.4%)	1.7%	4.6%	3.6%	12.2%	7.2%	8.2%	--
Net PP&E	9.6%	8.3%	9.3%	(2.7%)	(3.5%)	(0.9%)	0.8%	5.6%	5.9%	3.5%	--
Total Assets	(0.2%)	(0.1%)	3.1%	3.3%	2.1%	9.8%	10.9%	11.3%	11.4%	5.0%	--
Tangible Book Value	28.7%	58.9%	20.5%	1.5%	(17.2%)	(26.6%)	21.6%	7.4%	(10.0%)	(22.4%)	--
Common Equity	(3.3%)	(9.9%)	(0.5%)	4.0%	3.6%	10.8%	6.4%	7.4%	10.5%	9.0%	--
Cash from Ops.	(2.3%)	20.0%	7.5%	(5.2%)	(42.0%)	11.4%	30.4%	21.3%	53.9%	(1.1%)	--
Capital Expenditures	(4.3%)	(9.0%)	(4.4%)	(4.7%)	(20.9%)	(1.1%)	5.0%	8.3%	22.8%	1.4%	--
Levered Free Cash Flow	(1.8%)	24.4%	4.3%	(5.3%)	(45.4%)	12.7%	36.6%	24.3%	61.3%	(1.3%)	--
Unlevered Free Cash Flow	(7.2%)	41.0%	4.9%	(53.6%)	(94.9%)	16.4%	65.4%	223.7%	1,205.3%	(4.7%)	--
Dividend per Share	5.6%	5.6%	5.6%	12.2%	11.6%	212.6%	4.7%	0.0%	0.0%	(64.3%)	6.5%

CAGR Over Two Years

Total Revenue	4.5%	2.7%	1.4%	1.7%	(6.2%)	1.8%	5.0%	5.6%	6.5%	6.1%	9.3%
Gross Profit	2.4%	4.4%	2.6%	0.9%	(8.0%)	1.3%	4.5%	6.7%	7.4%	7.7%	11.3%
EBITDA	4.5%	9.6%	15.1%	0.8%	(5.8%)	4.3%	1.0%	16.7%	10.8%	(5.5%)	--
EBITA	5.3%	10.1%	18.3%	0.9%	(21.7%)	4.9%	0.7%	18.8%	(2.1%)	(5.8%)	5.4%
FRIT	0.0%	11.7%	23.6%	1.0%	(14.3%)	11.5%	(1.0%)	27.4%	7.6%	(11.0%)	7.0%
Earnings from Cont. Ops.	21.0%	(31.8%)	--	15.2%	(4.2%)	(5.0%)	(24.4%)	28.6%	5.8%	44.6%	8.7%
Net Income	21.0%	(31.8%)	--	15.2%	(4.2%)	(5.0%)	(24.4%)	28.6%	5.8%	44.6%	8.7%
Normalized Net Income	13.2%	5.6%	4.7%	8.3%	(13.7%)	5.9%	(4.8%)	10.6%	(3.3%)	11.8%	7.0%
Diluted EPS before Extra	21.9%	(30.6%)	--	16.5%	(3.2%)	(3.9%)	(23.8%)	29.2%	6.3%	44.1%	8.6%
Accounts Receivable	5.0%	6.1%	3.6%	2.5%	1.9%	1.9%	(1.9%)	2.9%	0.7%	0.4%	--
Inventory	(2.3%)	(1.8%)	1.4%	(0.8%)	3.4%	5.2%	4.2%	4.7%	4.4%	6.4%	--
Net PP&F	5.2%	4.1%	4.6%	1.1%	2.9%	3.6%	5.0%	1.4%	1.1%	1.3%	--
Total Assets	0.8%	(0.0%)	0.1%	(0.5%)	1.0%	4.7%	6.9%	7.2%	6.7%	7.4%	--
Tangible Book Value	25.8%	40.2%	(5.7%)	(0.9%)	3.3%	8.0%	21.0%	4.4%	(13.7%)	(24.5%)	--
Common Equity	(8.1%)	(11.3%)	(0.6%)	(1.6%)	0.1%	(0.1%)	2.9%	5.7%	7.0%	9.9%	--
Cash from Ops.	1.5%	9.6%	2.4%	(3.5%)	(24.6%)	15.6%	15.6%	7.2%	(5.5%)	4.9%	--
Capital Expenditures	10.2%	(2.9%)	0.8%	(2.5%)	(13.0%)	(5.1%)	0.2%	1.6%	(1.4%)	0.1%	--
Levered Free Cash Flow	0.3%	11.3%	2.8%	(3.7%)	(26.8%)	18.4%	19.4%	8.5%	(6.2%)	5.5%	--
Unlevered Free Cash Flow	(4.2%)	15.3%	0.6%	(42.7%)	(78.3%)	28.1%	31.7%	22.6%	(18.7%)	5.3%	--
Dividend per Share	6.3%	6.3%	6.3%	9.7%	8.5%	81.7%	5.1%	5.9%	5.6%	5.6%	5.6%

CAGR Over Three Years

Total Revenue	3.6%	5.2%	4.6%	5.2%	(0.9%)	2.4%	3.6%	3.7%	3.8%	4.7%	6.7%
Gross Profit	1.2%	4.0%	2.7%	3.3%	(3.3%)	3.5%	4.3%	4.4%	4.2%	5.4%	7.8%
FRITDA	2.9%	7.1%	3.7%	5.7%	(0.7%)	2.3%	8.9%	4.6%	6.7%	2.9%	--
EBITDA	2.8%	7.2%	3.4%	6.0%	(11.7%)	2.5%	11.1%	4.7%	(1.8%)	3.2%	4.8%
EBIT	(1.6%)	3.0%	(2.1%)	1.9%	(9.2%)	6.5%	13.3%	5.1%	4.3%	8.0%	5.7%
Earnings from Cont. Ops.	11.9%	(25.7%)	1.7%	9.4%	(1.8%)	(1.9%)	(154.5%)	12.4%	16.7%	(2.3%)	15.9%
Net Income	11.9%	(25.7%)	1.7%	9.4%	(1.8%)	(1.9%)	(154.5%)	12.4%	16.7%	(2.3%)	15.9%
Normalized Net Income	9.0%	3.3%	0.6%	4.3%	(8.8%)	6.6%	1.3%	8.3%	5.5%	8.9%	3.1%
Diluted EPS before Extra	13.3%	(24.4%)	2.8%	10.5%	(1.0%)	(1.0%)	(154.6%)	13.2%	17.5%	(1.6%)	16.5%
Accounts Receivable	6.7%	7.9%	7.4%	6.5%	3.3%	3.5%	0.2%	1.8%	1.8%	2.0%	--
Inventory	2.8%	2.6%	3.5%	(0.0%)	(1.0%)	0.3%	2.2%	3.4%	4.7%	6.2%	--
Net PP&E	4.5%	3.8%	5.4%	2.4%	2.3%	2.4%	3.3%	2.5%	3.9%	3.6%	--
Total Assets	3.5%	3.5%	3.8%	2.3%	1.2%	3.1%	3.6%	3.3%	4.3%	4.8%	--
Tangible Book Value	(197.7%)	(202.6%)	(202.6%)	(207.6%)	9.5%	13.0%	2.7%	1.8%	(1.4%)	(3.2%)	--
Common Equity	(5.7%)	(7.2%)	(5.5%)	(4.5%)	(4.3%)	(4.5%)	1.7%	1.3%	3.4%	2.8%	--
Cash from Ops.	9.2%	12.0%	(1.3%)	4.9%	(15.7%)	10.2%	11.0%	4.2%	(4.4%)	9.7%	--
Capital Expenditures	3.4%	0.4%	4.9%	3.7%	(1.3%)	(2.3%)	2.2%	1.0%	(2.4%)	(3.0%)	--
Levered Free Cash Flow	10.3%	13.6%	(2.6%)	5.1%	(18.1%)	11.8%	13.0%	4.8%	(4.7%)	11.4%	--
Unlevered Free Cash Flow	17.2%	20.6%	(8.0%)	7.8%	(64.1%)	15.7%	18.7%	2.0%	(15.0%)	16.1%	--
Dividend per Share	5.9%	5.9%	4.2%	8.1%	8.1%	52.3%	5.8%	6.3%	5.6%	5.6%	5.6%

CAGR Over Five Years

Total Revenue	1.1%	2.3%	2.6%	3.6%	0.6%	4.3%	4.8%	5.0%	4.8%	5.5%	6.5%
Gross Profit	0.2%	1.2%	1.9%	2.4%	(1.1%)	3.5%	3.8%	4.7%	3.6%	5.5%	6.0%
EBITDA	0.7%	3.4%	5.5%	4.0%	2.0%	4.3%	7.7%	6.1%	6.0%	1.8%	--
EBITA	0.7%	3.5%	5.7%	4.2%	(5.0%)	3.4%	9.1%	6.5%	0.8%	1.8%	4.2%
EBIT	(1.9%)	1.1%	2.8%	1.8%	(3.8%)	4.2%	5.5%	4.0%	2.0%	1.4%	1.5%
Earnings from Cont. Ops.	5.3%	(18.1%)	9.7%	6.1%	(4.3%)	1.1%	(11.6%)	6.8%	9.5%	(3.0%)	4.4%
Net Income	5.3%	(18.1%)	9.7%	6.1%	(4.3%)	1.1%	(11.6%)	6.8%	9.5%	(3.0%)	4.4%
Normalized Net Income	4.6%	2.2%	3.2%	5.5%	(2.1%)	6.5%	(0.2%)	4.8%	3.9%	6.6%	3.1%
Diluted EPS before Extra	6.6%	(16.8%)	11.0%	7.2%	(3.3%)	2.1%	(10.8%)	7.8%	10.4%	(2.2%)	5.1%
Accounts Receivable	3.6%	5.0%	5.7%	5.2%	4.1%	5.1%	4.8%	5.5%	4.3%	4.8%	--
Inventory	2.6%	1.7%	2.0%	1.9%	2.6%	3.2%	3.0%	4.0%	3.5%	4.1%	--
Net PP&E	2.4%	2.6%	2.9%	2.5%	2.5%	2.8%	3.4%	2.8%	3.1%	2.8%	--
Total Assets	2.8%	3.3%	3.9%	3.8%	3.7%	5.1%	5.6%	4.8%	4.8%	5.0%	--
Tangible Book Value	(196.1%)	(196.9%)	(202.2%)	(201.1%)	(196.9%)	(193.9%)	(203.2%)	(197.4%)	(193.0%)	(190.8%)	--
Common Equity	(4.9%)	(5.3%)	(3.1%)	(2.0%)	(2.4%)	(2.1%)	(2.3%)	(2.0%)	(0.7%)	(0.7%)	--
Cash from Ops.	1.5%	10.1%	6.8%	3.2%	(4.9%)	3.2%	10.4%	13.2%	3.1%	9.1%	--
Capital Expenditures	0.0%	(0.2%)	(3.4%)	2.9%	(2.9%)	(1.4%)	(0.6%)	1.2%	1.4%	0.3%	--
Levered Free Cash Flow	1.7%	11.7%	10.6%	3.3%	(5.3%)	3.7%	13.5%	17.0%	3.4%	10.3%	--
Unlevered Free Cash Flow	(0.9%)	17.2%	18.0%	(9.9%)	(39.3%)	3.0%	21.5%	(207.3%)	1.2%	14.3%	--
Dividend per Share	6.3%	6.3%	6.3%	7.6%	7.2%	31.7%	7.3%	6.1%	5.8%	5.8%	4.8%

Ticker: **jjj US EQUITY** | **jjj US EQUITY** Ascend | Currency Reporting Change | **USD**
 Period Type: **Annuals** | Consolidated: **Yes** | Accounting: **Mixed**

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

REVENUE											
Revenue by Product											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	--
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Pharmaceutical	25,779.00	27,426.00	28,490.00	32,313.00	31,430.00	33,464.00	36,256.00	40,734.00	42,201.00	45,572.00	52,082.00
Medical Devices	24,368.00	25,351.00	28,125.00	27,522.00	25,137.00	25,119.00	26,592.00	26,994.00	25,961.00	22,959.00	27,059.00
Consumer	14,883.00	14,447.00	14,697.00	14,496.00	13,507.00	13,307.00	13,602.00	13,853.00	13,897.00	14,053.00	14,634.00
Spine	-	-	-	-	-	-	-	-	-	-	-
Trauma	-	-	-	-	-	-	-	-	-	-	-
Hips	-	-	-	-	-	-	-	-	-	-	-
Knees	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
Revenue by Geography											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	--
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
United States	28,908.00	29,830.00	31,910.00	34,782.00	35,687.00	37,811.00	39,863.00	41,884.00	42,097.00	43,133.00	47,156.00
Europe	17,129.00	16,945.00	18,599.00	18,947.00	15,995.00	15,770.00	17,126.00	18,753.00	18,486.00	18,980.00	23,594.00
Asia-Pacific, Africa	12,575.00	13,242.00	13,382.00	13,442.00	12,347.00	12,575.00	13,420.00	14,831.00	15,555.00	15,136.00	17,275.00
Western Hemisphere excluding U.S.	6,418.00	7,207.00	7,421.00	7,160.00	6,045.00	5,734.00	6,041.00	6,113.00	5,941.00	5,335.00	5,750.00
International	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker: jnj US EQUITY	Sort Ascend	Currency Reporting Change USD
Period Type: Annuals	Consolidated: Yes	Accounting: Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Pension	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	--
For the Fiscal Period Ending	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	638.00	722.00	906.00	882.00	1,037.00	949.00	1,080.00	1,283.00	1,163.00	1,380.00	--
Interest Cost	853.00	878.00	908.00	1,018.00	988.00	927.00	927.00	996.00	1,096.00	955.00	--
Expected Return on Plan Assets	(1,108.00)	(1,236.00)	(1,447.00)	(1,607.00)	(1,809.00)	(1,962.00)	(2,041.00)	(2,212.00)	(2,322.00)	(2,461.00)	--
Pension Expense (Income)	781.00	865.00	1,055.00	743.00	971.00	422.00	594.00	923.00	593.00	790.00	--
Other Postretirement Cost											
Service Cost	149.00	175.00	196.00	211.00	257.00	224.00	247.00	269.00	274.00	287.00	--
Interest Cost	188.00	165.00	151.00	197.00	186.00	158.00	159.00	148.00	185.00	133.00	--
Expected Return on Plan Assets	(1.00)	(4.00)	(6.00)	(7.00)	(7.00)	(6.00)	(6.00)	(7.00)	(6.00)	(7.00)	--
Other Postretirement Benefits Expense (I	378.00	409.00	452.00	503.00	604.00	477.00	508.00	502.00	551.00	524.00	--
Pension Funded Status											
Fair Value of Plan Assets	13,736.00	17,536.00	20,901.00	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	--
Actual Return (Loss) on Plan Assets	(102.00)	1,926.00	3,573.00	2,078.00	298.00	2,286.00	4,274.00	(1,269.00)	6,185.00	5,524.00	--
Employer Contribution	1,135.00	1,838.00	565.00	1,176.00	752.00	838.00	664.00	1,140.00	908.00	870.00	--
Benefits Paid	(659.00)	(697.00)	(751.00)	(813.00)	(773.00)	(1,210.00)	(1,050.00)	(1,018.00)	(1,555.00)	(1,111.00)	--
Projected Benefit Obligation	17,424.00	21,829.00	21,488.00	26,889.00	25,855.00	28,116.00	33,221.00	31,670.00	37,188.00	43,300.00	--
Over(Under) Funded Pension	(3,688.00)	(4,293.00)	(587.00)	(4,314.00)	(3,601.00)	(4,483.00)	(4,817.00)	(4,852.00)	(4,987.00)	(5,105.00)	--
Accumulated Benefit Obligation	15,452.00	19,267.00	19,203.00	23,816.00	23,262.00	25,319.00	29,793.00	28,533.00	33,416.00	40,356.00	--
Pension Funding Ratio	78.83	80.33	97.27	83.96	86.07	84.06	85.50	84.68	86.59	88.21	--
Other Postretirement Funded Status											
Fair Value of Plan Assets	8.00	122.00	87.00	79.00	74.00	75.00	281.00	180.00	115.00	90.00	--
Actual Return (Loss) on Plan Assets	(1.00)	3.00	15.00	8.00	1.00	7.00	12.00	-	19.00	14.00	--
Employer Contribution	315.00	543.00	323.00	477.00	414.00	372.00	545.00	282.00	347.00	357.00	--
Benefits Paid	(320.00)	(432.00)	(373.00)	(493.00)	(420.00)	(378.00)	(351.00)	(383.00)	(431.00)	(396.00)	--
Projected Benefit Obligation	3,790.00	4,159.00	4,407.00	5,081.00	4,669.00	4,605.00	4,582.00	4,480.00	5,076.00	5,028.00	--
Over(Under) Funded Post Ret Benefits	(3,782.00)	(4,037.00)	(4,320.00)	(5,002.00)	(4,595.00)	(4,530.00)	(4,301.00)	(4,300.00)	(4,961.00)	(4,938.00)	--
Other Post-Retirement Funding Ratio	0.21	2.93	1.97	1.55	1.58	1.63	6.13	4.02	2.27	1.79	--
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	8.44	8.45	8.46	8.46	8.53	8.55	8.43	8.46	8.31	8.12	--
Discount Rate used on Plan Liabilities	5.08	4.25	4.78	3.78	4.11	3.78	3.30	3.76	2.91	2.14	--
Rate of Compensation Increase	4.15	4.08	4.08	4.08	4.05	4.02	4.01	3.98	3.99	4.00	--
Other Postretirement Benefits											
Expected Return on Plan Assets	9.00	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	5.43	4.55	5.25	5.25	4.31	4.77	4.63	3.85	4.45	3.04	--
Health Care Cost Trend Projected(next y	7.50	6.50	6.50	6.00	6.60	6.32	6.33	6.12	5.87	5.68	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	13,736.00	17,536.00	20,901.00	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	--
Asset Category - Equities %	48.78	46.24	50.49	77.00	79.00	75.00	76.00	71.00	74.00	66.00	--
Asset Category - Debt %	8.12	9.39	5.82	23.00	21.00	25.00	24.00	29.00	26.00	34.00	--
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Other %	43.10	44.37	43.69	-	-	-	-	-	-	-	--
Expected Pension Payments											
Year 1	354.00	316.00	778.00	793.00	839.00	897.00	970.00	1,062.00	1,126.00	1,257.00	--
Year 2	277.00	221.00	794.00	813.00	872.00	908.00	1,007.00	1,104.00	1,172.00	1,292.00	--
Year 3	216.00	220.00	840.00	868.00	911.00	958.00	1,057.00	1,182.00	1,234.00	1,388.00	--
Year 4	218.00	220.00	890.00	907.00	967.00	1,010.00	1,131.00	1,257.00	1,323.00	1,424.00	--
Year 5	218.00	220.00	933.00	963.00	1,031.00	1,081.00	1,190.00	1,332.00	1,359.00	1,494.00	--
Beyond Year 5	1,112.00	1,121.00	6,071.00	5,858.00	6,098.00	6,416.00	7,062.00	7,679.00	7,945.00	8,795.00	--
Expected Postretirement Benefits											
Year 1	--	--	313.00	316.00	331.00	325.00	322.00	375.00	437.00	427.00	--
Year 2	--	--	309.00	309.00	322.00	315.00	312.00	397.00	450.00	440.00	--
Year 3	--	--	305.00	306.00	315.00	311.00	306.00	411.00	466.00	453.00	--
Year 4	--	--	302.00	303.00	312.00	307.00	301.00	428.00	479.00	465.00	--
Year 5	--	--	299.00	300.00	310.00	304.00	297.00	413.00	494.00	417.00	--
Beyond Year 5	--	--	1,469.00	1,475.00	1,499.00	1,465.00	1,395.00	2,273.00	2,356.00	2,273.00	--

